Leading biopharma companies report key advances and challenges in cancer and rare disease therapeutics. Diamedica demonstrated early efficacy of DM199 in preeclampsia, an area with no approved therapies. I-Mab strengthened rights to its CLDN18.2-targeted bispecific antibody givastomig through Bridge Health acquisition, aiming for a potential best-in-class solid tumor drug with high response rates in trials. AstraZeneca’s anselamimab failed a Phase 3 trial for light chain amyloidosis despite encouraging subgroup results. Prime Medicine received additional funding from the Cystic Fibrosis Foundation to develop gene editing therapy. Biogen and other firms are advancing antibodies and modulators for diseases including pulmonary fibrosis and myocardial hypertrophy.